Advertisement

Clinical Rheumatology

, Volume 36, Issue 5, pp 1189–1196 | Cite as

Early diagnosis of early-onset sarcoidosis: a case report with functional analysis and review of the literature

  • Yusuke Takeuchi
  • Tomonari Shigemura
  • Norimoto Kobayashi
  • Naoe Kaneko
  • Tomoyuki Iwasaki
  • Kisei Minami
  • Keiko Kobayashi
  • Junya Masumoto
  • Kazunaga Agematsu
Case Based Review

Abstract

This study examined the pathogenesis of early-onset sarcoidosis (EOS) in a patient with a rare NOD2 mutation and surveyed the literature to identify the hallmark features for early diagnosis. An infant girl suffering from prolonged fever and skin rash of multiple pinkish papules and subsequent erythema nodosum was referred to our institution. Skin biopsy and DNA sequencing were performed along with cytokine profiling of the patient’s serum and stimulated mononuclear cells. NF-κB activation was analyzed using transfected cells. Multiple non-caseating granuloma inclusions were recognized in biopsy specimens obtained from the patient’s rash. DNA sequencing revealed a very rare heterozygous Met513Thr (M513T) mutation in NOD2. Mononuclear cells produced a low amount of IL-1β upon stimulation as compared with normal control cells. Mutated NOD2 transfection enhanced NF-κB activation. We suspected that the M513T mutation in NOD2 decreased IL-1β production and enhanced NF-κB activation, which was likely responsible for the patient’s granuloma involvement. A comprehensive review of the literature on 30 cases of sporadic type of EOS revealed that all patients had cutaneous manifestations, with all but one displaying granulation. A majority of EOS patients have R334W/Q. But about half of sporadic EOS had NOD2 mutations other than R334W/Q, as in the present case. Accordingly, skin rash with granuloma formation and specific NOD2 mutations may represent early diagnostic hallmarks of EOS in infants with persistent inflammation.

Keyword

Early-onset sarcoidosis IL-1β NF-κB activation NOD2/CARD15 

Notes

Acknowledgements

We express our sincere appreciation to the doctors in the Department of Dermatology at Shinshu University Hospital for skin biopsy procedures and Dr. S. Ohara for performing DNA sequencing.

Compliance with ethical standards

This genetic analysis was approved by the institutional review board of Shinshu University and performed in accordance with the ethical tenets set forth in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from the patient’s parents for publication of this case report and its accompanying images.

Disclosures

None.

References

  1. 1.
    Blau EB (1985) Familial granulomatous arthritis, iritis, and rash. J Pediatr 107:689–693CrossRefPubMedGoogle Scholar
  2. 2.
    Rose CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey MP et al (2005) Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 32:373–375PubMedGoogle Scholar
  3. 3.
    Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R et al (2001) CARD15 mutations in Blau syndrome. Nat Genet 29:19–20CrossRefPubMedGoogle Scholar
  4. 4.
    Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J et al (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease J Biol Chem 278:5509–5512PubMedGoogle Scholar
  5. 5.
    Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nunez G et al (2008) A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J 27:373–383CrossRefPubMedGoogle Scholar
  6. 6.
    Shigemura T, Kaneko N, Kobayashi N, Kobayashi K, Takeuchi Y, Nakano N et al (2016) Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behcet’s disease. RMD open 2:e000223CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F et al (2003) Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 100:3455–3460CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S et al (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105:1195–1197CrossRefPubMedGoogle Scholar
  9. 9.
    Martin TM, Zhang Z, Kurz P, Rose CD, Chen H, Lu H et al (2009) The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 60:611–618CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Masumoto J, Yamazaki T, Ohta K, Nakayama J, Agematsu K (2009) Interleukin-1beta suppression in Blau syndrome: comment on the article by Martin et al. Arthritis Rheum 60:2544–2545CrossRefPubMedGoogle Scholar
  11. 11.
    Jabs DA, Houk JL, Bias WB, Arnett FC (1985) Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 78:801–804CrossRefPubMedGoogle Scholar
  12. 12.
    Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S et al (2009) Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 60:242–250CrossRefPubMedGoogle Scholar
  13. 13.
    Kanazawa N, Matsushima S, Kambe N, Tachibana T, Nagai S, Miyachi Y (2004) Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Dermatol 122:851–852CrossRefPubMedGoogle Scholar
  14. 14.
    La Torre F, Lapadula G, Cantarini L, Lucherini OM, Iannone F (2015) Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. Clin Rheumatol 34:391–395CrossRefPubMedGoogle Scholar
  15. 15.
    Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM et al (2014) Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 13:1220–1229CrossRefPubMedGoogle Scholar
  16. 16.
    Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P et al (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 56:3805–3813CrossRefPubMedGoogle Scholar
  17. 17.
    Sugiyama R, Agematsu K, Migita K, Nakayama J, Mokuda S, Ogura F et al (2014) Defect of suppression of inflammasome-independent interleukin-8 secretion from SW982 synovial sarcoma cells by familial Mediterranean fever-derived pyrin mutations. Mol Biol Rep 41:545–553CrossRefPubMedGoogle Scholar
  18. 18.
    Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L (2015) Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn’s disease. RMD open 1:e000097CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Janssen CE, Rose CD, De Hertogh G, Martin TM, Bader Meunier B, Cimaz R et al (2012) Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol 129:1076–1084CrossRefPubMedGoogle Scholar
  20. 20.
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286–290CrossRefPubMedGoogle Scholar
  21. 21.
    Milman N, Andersen CB, Hansen A, van Overeem HT, Nielsen FC, Fledelius H et al (2006) Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS 114:912–919CrossRefPubMedGoogle Scholar
  22. 22.
    Sakurai Y, Nakajima M, Kamisue S, Nishimura Y, Ueda T, Miyagawa S et al (1997) Preschool sarcoidosis mimicking juvenile rheumatoid arthritis: the significance of gallium scintigraphy and skin biopsy in the differential diagnosis. Acta Paediatr Jpn 39:74–78CrossRefPubMedGoogle Scholar
  23. 23.
    Yasui K, Yashiro M, Tsuge M, Manki A, Takemoto K, Yamamoto M et al (2010) Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum 62:250–257CrossRefPubMedGoogle Scholar
  24. 24.
    Ukae S, Tsutsumi H, Adachi N, Takahashi H, Kato F, Chiba S (1994) Preschool sarcoidosis manifesting as juvenile rheumatoid arthritis: a case report and a review of the literature of Japanese cases. Acta Paediatr Jpn 36:515–518CrossRefPubMedGoogle Scholar
  25. 25.
    Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F (2010) NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin Immunol 134:251–261CrossRefPubMedGoogle Scholar
  26. 26.
    Ikeda K, Kambe N, Takei S, Nakano T, Inoue Y, Tomiita M et al (2014) Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome. Arthritis Res Ther 16:R89CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yotsumoto S, Takahashi Y, Takei S, Shimada S, Miyata K, Kanzaki T (2000) Early onset sarcoidosis masquerading as juvenile rheumatoid arthritis. J Am Acad Dermatol 43:969–971CrossRefPubMedGoogle Scholar
  28. 28.
    Jain L, Gupta N, Reddy MM, Mittal R, Barik MR, Panigrahi B et al. (2016) A novel mutation in helical domain 2 of NOD2 in sporadic Blau syndrome. Ocul Immunol Inflamm :1–3.Google Scholar
  29. 29.
    Meiorin SM, Espada G, Costa CE, Tartara A, De Matteo E, Wouters C et al (2007) Granulomatous nephritis associated with R334Q mutation in NOD2. J Rheumatol 34:1945–1947PubMedGoogle Scholar
  30. 30.
    Priori R, Bombardieri M, Spinelli FR, Merlin F, Miceli-Richard C, La Cava M et al (2004) Sporadic Blau syndrome with a double CARD15 mutation. Report of a case with lifelong follow-up. Sarcoidosis Vasc Diffuse Lung Dis 21:228–231PubMedGoogle Scholar
  31. 31.
    Okada S, Konishi N, Tsumura M, Shirao K, Yasunaga S, Sakai H et al (2009) Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15. Rheumatology (Oxford) 48:706–707CrossRefGoogle Scholar
  32. 32.
    Sakai H, Ito S, Nishikomori R, Takaoka Y, Kawai T, Saito M et al (2010) A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. Rheumatology (Oxford) 49:194–196CrossRefGoogle Scholar
  33. 33.
    Stoevesandt J, Morbach H, Martin TM, Zierhut M, Girschick H, Hamm H (2010) Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. Pediatr Dermatol 27:69–73CrossRefPubMedGoogle Scholar
  34. 34.
    Martin J, Kodjikian L, Duquesne A, Le Scanff J, Seve P (2011) Blau syndrome. QJM 104:997–998CrossRefPubMedGoogle Scholar
  35. 35.
    Raiji VR, Miller MM, Jung LK (2011) Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 15:205–207CrossRefPubMedGoogle Scholar
  36. 36.
    Jimenez-Martinez MC, Cruz F, Groman-Lupa S, Zenteno JC (2011) Immunophenotyping in peripheral blood mononuclear cells, aqueous humour and vitreous in a Blau syndrome patient caused by a novel NOD2 mutation. Int J Immunogenet 38:233–242CrossRefPubMedGoogle Scholar
  37. 37.
    Sharma SM, Martin TM, Rose CD, Dick AD, Ramanan AV (2011) Distinguishing between the innate immune response due to ocular inflammation and infection in a child with juvenile systemic granulomatous disease treated with anti-TNFalpha monoclonal antibodies. Rheumatology (Oxford) 50:990–992CrossRefGoogle Scholar
  38. 38.
    Inoue Y, Kawaguchi Y, Shimojo N, Yamaguchi K, Morita Y, Nakano T et al (2013) A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/early-onset sarcoidosis? Mod Rheumatol 23:837–839CrossRefPubMedGoogle Scholar
  39. 39.
    Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V et al (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 65:513–518CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Chauhan K, Michet C (2014) A case of blau syndrome. Case Rep Rheumatol 2014:216056PubMedPubMedCentralGoogle Scholar
  41. 41.
    Arvesen KB, Herlin T, Larsen DA, Koppelhus U, Ramsing M, Skytte AB et al. (2016) Diagnosis and treatment of Blau syndrome/early-onset sarcoidosis, an autoinflammatory granulomatous disease, in an infant. Acta Derm Venereol.Google Scholar
  42. 42.
    Zeybek C, Basbozkurt G, Gul D, Demirkaya E, Gok F (2015) A new mutation in blau syndrome. Case Rep Rheumatol 2015:463959PubMedPubMedCentralGoogle Scholar
  43. 43.
    Paparizos SC, Goldstein DA, Bouhenni RA, Steiner S, Dunmire JJ, Edward DP (2012) Immunohistochemical evidence of specific iris involvement in Blau syndrome. Ocul Immunol Inflamm 20:471–474CrossRefPubMedGoogle Scholar
  44. 44.
    Coto-Segura P, Mallo-Garcia S, Costa-Romero M, Arostegui JI, Yague J, Ramos-Polo E et al (2007) A sporadic case of early-onset sarcoidosis resembling Blau syndrome due to the recurrent R334W missense mutation on the NOD2 gene. Br J Dermatol 157:1257–1259CrossRefPubMedGoogle Scholar
  45. 45.
    Ohga S, Ichino K, Urabe K, Ishimura M, Takada H, Nishikomori R et al (2008) Early-onset sarcoidosis mimicking refractory cutaneous histiocytosis. Pediatr Blood Cancer 50:723–726CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Yusuke Takeuchi
    • 1
  • Tomonari Shigemura
    • 1
  • Norimoto Kobayashi
    • 1
  • Naoe Kaneko
    • 2
  • Tomoyuki Iwasaki
    • 2
  • Kisei Minami
    • 3
  • Keiko Kobayashi
    • 4
  • Junya Masumoto
    • 2
  • Kazunaga Agematsu
    • 4
  1. 1.Department of PediatricsShinshu University School of MedicineMatsumotoJapan
  2. 2.Department of PathologyEhime University Proteo-Science Center and Graduate School of MedicineEhimeJapan
  3. 3.Nagano Children’s HospitalAzuminoJapan
  4. 4.Department of Infection and Host Defense, Graduate School of MedicineShinshu UniversityMatsumotoJapan

Personalised recommendations